Amsel Medical Corporation

Amsel Medical Corporation develops minimally invasive surgical occlusion devices for vessel and tubular structure closure. The company's primary product, SCureClamp™ with Interdigitation Occlusion Technology (iDOT™), is a mechanical surgical clamping device FDA-cleared and CE-marked for closing blood vessels, arteries, veins, and ducts during surgical and interventional procedures. The device employs a unique transfixing mechanism delivered through an 18-gauge needle, providing permanent, non-chemical, non-thermal occlusion similar to hand-sewn transfixion sutures. Key design features include anchoring technology to prevent slippage, accommodation of vessels 2.0–7.0 mm in diameter, and ultrasound-guided deployment. Amsel's SCureClamp targets multiple surgical specialties including vascular surgery, general surgery (bariatric, cardiac, oncology), trauma management, and interventional radiology. In vascular applications, the device addresses limitations of current perforator treatments (lasers, RF, glue, sclerotherapy), which average 75–80% efficacy and lack permanent solutions. Clinical evidence from peer-reviewed publications in the Journal of Vascular Surgery, Surgical Endoscopy, and Journal of Surgical Research demonstrates preclinical efficacy in porcine models. The company is also developing a temporary clamping variant for military trauma applications, specifically targeting non-compressible and junctional hemorrhage in prehospital environments. Amsel Medical was awarded a prestigious U.S. Air Force AFWERX Phase 2 SBIR grant for this development. The company's devices are indicated for use by vein physicians, general surgeons, vascular surgeons, cardiovascular surgeons, interventional radiologists, and military medical personnel. Manufacturing and regulatory compliance align with FDA 510(k) and CE Mark standards.